Clopidogrel Responsiveness in Patients Undergoing Percutaneous Coronary Intervention using Multiplate Analyzer: Frequency and Outcomes

Q4 Pharmacology, Toxicology and Pharmaceutics
Murad A. Khadim, Hasan A. Farhan, Muthanna ., Muthanna H Al-Quraishi
{"title":"Clopidogrel Responsiveness in Patients Undergoing Percutaneous Coronary Intervention using Multiplate Analyzer: Frequency and Outcomes","authors":"Murad A. Khadim, Hasan A. Farhan, Muthanna ., Muthanna H Al-Quraishi","doi":"10.25258/ijddt.13.3.53","DOIUrl":null,"url":null,"abstract":"Objectives: Over and under response to dual antiplatelet therapy (DAPT) can lead to bleeding and thrombotic events in patients undergoing coronary stent placement. The present study aimed to assess the platelet response to clopidogrel in patient undergoing percutaneous coronary intervention (PCI) using Multiplate Analyzer. The primary outcome in the present study was the short-term incidence of stent thrombosis and bleeding events. Background: Multiple electrode aggregometry is a rapid and standardized tool to for diagnosis of platelet defects and monitoring response to DAPT. Methods: A hospital-based, prospective study was conducted on 431 patients who underwent PCI from September 2016 to November 2017 and received clopidogrel therapy. The platelet aggregometry was done using a Multiplate analyzer (Dynabyte, Munich, Germany). Patients were followed for 30 days to assess the incidence of stent thrombosis and bleeding. Results: The patients’ mean age was 58 ± 6.7 years. A total of 40% of the patients were diabetic and 7.7% had chronic renal failure. The rate of clopidogrel non-responders was 10.7%, while clopidogrel over-responders were 18.3%. Patients with diabetes and chronic renal failure had significantly lower platelet responsiveness (40.1% with p < 0.05 and 7.7% with p <0.005, respectively). Smoking was significantly associated with platelet over-responsiveness (39.4%, p < 0.001). Patients with low platelet responsiveness to clopidogrel were associated with an increased risk of definite stent thrombosis (p < 0.005), while increasing bleeding risk was significantly associated with over-responsiveness to patients to clopidogrel (p <0.001). Conclusions: Antiplatelet responsiveness showing individual variability with increased risk of stent thrombosis among the cases with no response to the effect of clopidogrel and high risk of bleeding with the over-responsiveness group.","PeriodicalId":13851,"journal":{"name":"International Journal of Drug Delivery Technology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Delivery Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25258/ijddt.13.3.53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Over and under response to dual antiplatelet therapy (DAPT) can lead to bleeding and thrombotic events in patients undergoing coronary stent placement. The present study aimed to assess the platelet response to clopidogrel in patient undergoing percutaneous coronary intervention (PCI) using Multiplate Analyzer. The primary outcome in the present study was the short-term incidence of stent thrombosis and bleeding events. Background: Multiple electrode aggregometry is a rapid and standardized tool to for diagnosis of platelet defects and monitoring response to DAPT. Methods: A hospital-based, prospective study was conducted on 431 patients who underwent PCI from September 2016 to November 2017 and received clopidogrel therapy. The platelet aggregometry was done using a Multiplate analyzer (Dynabyte, Munich, Germany). Patients were followed for 30 days to assess the incidence of stent thrombosis and bleeding. Results: The patients’ mean age was 58 ± 6.7 years. A total of 40% of the patients were diabetic and 7.7% had chronic renal failure. The rate of clopidogrel non-responders was 10.7%, while clopidogrel over-responders were 18.3%. Patients with diabetes and chronic renal failure had significantly lower platelet responsiveness (40.1% with p < 0.05 and 7.7% with p <0.005, respectively). Smoking was significantly associated with platelet over-responsiveness (39.4%, p < 0.001). Patients with low platelet responsiveness to clopidogrel were associated with an increased risk of definite stent thrombosis (p < 0.005), while increasing bleeding risk was significantly associated with over-responsiveness to patients to clopidogrel (p <0.001). Conclusions: Antiplatelet responsiveness showing individual variability with increased risk of stent thrombosis among the cases with no response to the effect of clopidogrel and high risk of bleeding with the over-responsiveness group.
使用多板分析仪进行经皮冠状动脉介入治疗的患者的氯吡格雷反应性:频率和结果
目的:双重抗血小板治疗(DAPT)反应过度和反应不足可导致冠状动脉支架置入术患者出血和血栓形成事件。本研究旨在利用多板分析仪评估经皮冠状动脉介入治疗(PCI)患者对氯吡格雷的血小板反应。本研究的主要结局是支架内血栓形成和出血事件的短期发生率。背景:多电极聚集是一种快速、标准化的诊断血小板缺陷和监测DAPT反应的工具。方法:对2016年9月至2017年11月行PCI治疗并接受氯吡格雷治疗的431例患者进行前瞻性研究。血小板聚集使用多板分析仪(Dynabyte, Munich, Germany)。随访30天,评估支架内血栓和出血的发生率。结果:患者平均年龄58±6.7岁。其中糖尿病患者占40%,慢性肾功能衰竭患者占7.7%。氯吡格雷无反应率为10.7%,氯吡格雷过度反应率为18.3%。糖尿病合并慢性肾功能衰竭患者血小板反应性明显降低(p <组40.1%;0.05和7.7% (p <0.005)。吸烟与血小板过度反应性显著相关(39.4%,p <0.001)。血小板对氯吡格雷反应性低的患者与支架内血栓形成的风险增加相关(p <0.005),而出血风险增加与患者对氯吡格雷的过度反应显著相关(p <0.001)。结论:抗血小板反应性表现出个体差异,在氯吡格雷无效和高出血风险组中,支架血栓形成风险增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Drug Delivery Technology
International Journal of Drug Delivery Technology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
0.70
自引率
0.00%
发文量
0
期刊介绍: International Journal of Drug Delivery Technology (IJDDT) provides the forum for reporting innovations, production methods, technologies, initiatives and the application of scientific knowledge to the aspects of pharmaceutics, including controlled drug release systems, drug targeting etc. in the form of expert forums, reviews, full research papers, and short communications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信